Meningococcal (group B) multicomponent recombinant adsorbed vaccine
Phase 3Completed 0 watching 0 views this week๐ Rising
77
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Meningitis, Meningococcal, Serogroup B
Conditions
Meningitis, Meningococcal, Serogroup B
Trial Timeline
Dec 1, 2014 โ Apr 1, 2015
NCT ID
NCT02305446About Meningococcal (group B) multicomponent recombinant adsorbed vaccine
Meningococcal (group B) multicomponent recombinant adsorbed vaccine is a phase 3 stage product being developed by Novartis for Meningitis, Meningococcal, Serogroup B. The current trial status is completed. This product is registered under clinical trial identifier NCT02305446. Target conditions include Meningitis, Meningococcal, Serogroup B.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02305446 | Phase 3 | Completed |
Competing Products
20 competing products in Meningitis, Meningococcal, Serogroup B